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Regulation of BubR1 is central to the control of APC/C
activity. We have found that BubR1 forms a complex with
PCAF and is acetylated at lysine 250. Using mass spectro-
metry and acetylated BubR1-speciﬁc antibodies, we have
conﬁrmed that BubR1 acetylation occurs at prometaphase.
Importantly, BubR1 acetylation was required for check-
point function, through the inhibition of ubiquitin-
dependent BubR1 degradation. BubR1 degradation began
before the onset of anaphase. It was noted that the pre-
anaphase degradation was regulated by BubR1 acetylation.
Degradation of an acetylation-mimetic form, BubR1–
K250Q, was inhibited and chromosome segregation in
cells expressing BubR1–K250Q was markedly delayed.
By contrast, the acetylation-deﬁcient mutant, BubR1–
K250R, was unstable, and mitosis was accelerated in
BubR1–K250R-expressing cells. Furthermore, we found
that APC/C–Cdc20 was responsible for BubR1 degradation
during mitosis. On the basis of our collective results, we
propose that the acetylation status of BubR1 is a molecular
switch that converts BubR1 from an inhibitor to a sub-
strate of the APC/C complex, thus providing an efﬁcient
way to modulate APC/C activity and mitotic timing.
The EMBO Journal (2009) 28, 2077–2089. doi:10.1038/
emboj.2009.123; Published online 30 April 2009
Subject Categories: proteins; cell cycle
Keywords: acetylation; APC/C; BubR1; Cdc20; spindle
assembly checkpoint (SAC)
Introduction
Genetic integrity through accurate chromosome segregation
requires the spindle-assembly checkpoint (SAC; Musacchio
and Hardwick, 2002; Bharadwaj and Yu, 2004; Taylor et al,
2004). The activated SAC inhibits the anaphase-promoting
complex (APC/C), a multicomplex E3 ligase that is respon-
sible for destroying securin and Cyclin B (Yu, 2002). When
this checkpoint fails, cells die or become aneuploid—a hall-
mark of cancer (Rieder and Maiato, 2004; Kops et al, 2005).
BubR1 is essential for the SAC and checkpoint signalling
(Yu, 2002). Importantly, BubR1 binds directly to Cdc20, the
WD domain-containing coactivator of the APC/C complex
during mitosis (Tang et al, 2001; Yu, 2002; Chan and Yen,
2003). Cdh1 is another coactivator that is activated when it is
no longer phosphorylated by Cdk1, and replaces Cdc20 in
binding and activating the APC/C complex. Thus, Cdc20
serves as a coactivator of the APC/C E3 ligase until mitotic
exit (Passmore and Barford, 2005; Peters, 2006; Thornton and
Toczyski, 2006; Yu, 2007). The importance of BubR1 in the
SAC is reﬂected by the observation that BubR1 forms the
mitotic checkpoint complex (MCC) composed of Mad2, Bub3,
BubR1, and Cdc20 and inactivates the APC/C–Cdc20 complex
(Sudakin et al, 2001). A recent report suggested an alternative
model for SAC activation, where Mad2 only loads Cdc20 onto
BubR1 and then leaves the complex. Consequently, the
Bub3–BubR1–Cdc20 complex is presented to the APC/C
complex, followed by Cdc20 ubiquitination and degradation
to maintain the SAC (Nilsson et al, 2008). In any model
presented, BubR1 plays a central role in binding to and
regulating the APC/C–Cdc20 complex.
It should be noted that BubR1 binds to APC as well as to
Cdc20 (Chan et al, 1999; Sudakin et al, 2001; Morrow et al,
2005). BubR1, similar to its orthologue Mad3 in yeast (Burton
and Solomon, 2007; Sczaniecka et al, 2008), has a D-box-like
motif and two KEN boxes, which serve as destruction signals
for the APC/C complex (Glotzer et al, 1991; King et al, 1996b;
Pﬂeger and Kirschner, 2000). This suggests that BubR1 can be
regulated by APC/C-mediated destruction. In this vein, it is
noteworthy that BubR1 levels decrease late in mitosis (Chan
et al, 1999). However, data from yeast Mad3, a homologue of
mammalian BubR1, indicated that BubR1 is not degraded
through APC/C-mediated polyubiquitination. Instead, BubR1
functions as a pseudosubstrate of the APC/C complex by
competing with genuine substrates of the APC/C complex for
the same Cdc20-binding sites (D-box and KEN box) (Burton
and Solomon, 2007). Therefore, it remains to be elucidated
whether BubR1 is regulated through destruction by the
APC/C complex.
Regarding the regulation of BubR1 protein levels and its
consequences in checkpoint activity, it has been shown that
the levels of BubR1 during mitosis are crucial for mitotic
timing. siRNA knockdown of BubR1 resulted in mitosis
acceleration and checkpoint abrogation (Meraldi et al,
2004). In addition, BubR1 is required for the assembly of
SAC components (Chen, 2002). Therefore, regulation of
BubR1 levels might be an essential regulatory step in check-
point activity.
BubR1 is a kinase, whereas its yeast homologue, Mad3,
lacks a kinase domain. The kinase activity of BubR1 is
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2077stimulated by the microtubule motor protein, CENP-E, and
is required for checkpoint maintenance and signalling in
metazoans (Abrieu et al, 2000; Mao et al, 2003, 2005;
Weaver et al, 2003). Phosphorylation of BubR1 in mitosis
by kinases such as Cdk1, Aurora B, and Plk1 is essential for
monitoring stable spindle attachments to kinetochores and
tension. BubR1 phosphorylation is also required for check-
point signalling (Ditchﬁeld et al, 2003; Lampson and Kapoor,
2005; Elowe et al, 2007; Wong and Fang, 2007; Huang et al,
2008).
In this study, we show that BubR1 is acetylated exclusively
at the prometaphase stage. We found that BubR1 is degraded
during mitosis through APC/C–Cdc20-mediated ubiquitina-
tion. It is noteworthy that the acetylation of BubR1 inhibits its
degradation by the APC/C–Cdc20 complex during mitosis,
and this mechanism controls the timing of mitosis. Our results
indicate that the acetylation status of BubR1 provides a mole-
cular switch that controls the timely activation of the APC/C
complex, thereby serving as a regulatory step for the SAC.
Results
BubR1 binds to and is acetylated by PCAF
at prometaphase kinetochores
Protein modiﬁcations such as phosphorylation,
SUMOylation, and acetylation contribute to the control of
cell-cycle progression. While studying the regulation of
BubR1 activity, we found that BubR1 might be controlled
by acetylation. Asynchronously growing cells and nocoda-
zole-arrested HeLa cells were compared and tested for the
possibility of BubR1 acetylation. Immunoprecipitation (IP)
followed by WB analysis showed that BubR1 might be
acetylated in nocodazole-arrested cells (Figure 1A).
Next, we tested the binding ability of BubR1 to p300, CBP,
and PCAF to verify whether BubR1 was capable of binding to
acetyltransferase and being acetylated. In IP and WB, BubR1
interacted with PCAF but not with p300 or CBP acetyltrans-
ferases (Supplementary Figure 1). It is noteworthy that
BubR1–PCAF complex formation was detected in nocoda-
zole-arrested cells but was barely detectable in asynchronous
cells (Figure 1B). This suggests the possibility that PCAF
acetylates BubR1 and this acetylation might play a role in the
control of BubR1 activity.
We then examined the location of the BubR1–PCAF com-
plex formation because BubR1 localizes to kinetochores in
mitosis. The localization of BubR1 to kinetochores is essen-
tial for SAC function; it monitors bipolar spindle attachment
and chromosome alignment (Ditchﬁeld et al, 2003), thereby
regulating the APC/C complex and the metaphase–anaphase
transition (Yu, 2002; Chan and Yen, 2003). Metaphase chro-
mosomal spreads were prepared and subjected to an immu-
noﬂuorescence assay with anti-PCAF and anti-BubR1
antibodies. The assays showed that BubR1 and PCAF colo-
calized at kinetochores (Figure 1C and D). Consistent with in
vivo complex formation between BubR1 and PCAF at prome-
taphase kinetochores, we observed that BubR1 could be
acetylated by PCAF. Recombinant BubR1, as well as immu-
noprecipitated BubR1, was acetylated by PCAF during in vitro
acetylation assays (Figure 1E and F).
Next, we asked whether sustained BubR1 acetylation
affected mitotic cell-cycle progression. As a ﬁrst step towards
answering this question, we treated cells in mitosis with the
pan-HDAC inhibitor trichostatin A (TSA). HeLa cells were
synchronized at prometaphase by nocodazole treatment fol-
lowed by mitotic shake-off. Subsequently, synchronized cells
were either released from the mitotic arrest by washing out
nocodazole (Figure 2A, left panel), or kept in nocodazole to
maintain mitotic arrest (Figure 2A, right panel). The effects of
TSA treatment on BubR1 levels were analysed in both cases,
with cycloheximide (CHX) treatment included to control for
the effects of de novo protein synthesis. Cells were collected
at the indicated time points and were analysed for BubR1
levels (Figure 2A) and cell-cycle proﬁles (Figure 2B).
Interestingly, BubR1 levels decreased markedly from the
initial time point of analysis in cells progressing through
mitosis (Figure 2A, left panel, none), and were further
decreased by CHX treatment (Figure 2A, left panel,
þCHX). When cells were arrested in mitosis by continuous
nocodazole treatment, BubR1 levels were maintained
(Figure 2A, right panel, none). However, when CHX was
added, BubR1 levels decreased in the nocodazole-arrested
condition (Figure 2A, right panel, þCHX). Taken together,
these results suggest that, similar to Cdc20 (Nilsson et al,
2008), BubR1 is not only degraded but also continuously
synthesized during mitosis.
TSA treatment resulted in sustained levels of BubR1 rela-
tive to the levels after CHX treatment in cells progressing
through mitosis (Figure 2A, left panel, TSA and TSAþCHX)
and in cells blocked for exit from mitosis (Figure 2A, right
panel, TSA and TSAþCHX). Concomitantly, mitotic exit
was delayed for at least 5h, until the end of the time course,
by treatment with TSA (Figure 2B, left panel, TSA and TSA
þCHX), whereas control or CHX-treated cells exited from
mitosis 1h after nocodazole release (Figure 2B, left panel,
none and CHX). In all cases of continuous nocodazole treat-
ment, cells did not exit from mitosis (Figure 2A, right panel).
The fact that TSA treatment resulted in the stabilization of
BubR1 levels suggests that BubR1 might be one of the targets
of TSA during mitosis. Taken together with the results from
Figure 1, BubR1 is likely to be acetylated in mitosis, which
probably results in the inhibition of its degradation. In this
regard, our observation that BubR1 interacted with HDAC 1–3
in transfected cells (Supplementary Figure 3) suggests the
intriguing possibility that the BubR1 acetylation state might
regulate BubR1 function and progression through mitosis.
BubR1 Lysine 250 (K250) is acetylated
To identify the acetylation site, we made a series of BubR1
deletion constructs, transfected them into 293T cells, and
analysed the acetylation domain by IP and WB. The N-
terminal region of BubR1 contained the acetylation domain
(Supplementary Figure 4). Further in vitro acetylation assays
showed that BubR1 amino acids 221–299 (DBR2–3) con-
tained acetylated lysine residues (Figure 3A and B). In
parallel, mass spectrometry analysis was carried out with
full-length BubR1 puriﬁed from insect cells and K250 was
identiﬁed as the site of acetylation (Supplementary Figure 5).
By means of in vitro mutagenesis and acetylation assays, we
conﬁrmed that K250 was the acetylation site (Figure 3C and
Supplementary Figure 6). To verify that K250 was acetylated
in vivo, interphase and prometaphase HeLa cells prepared by
nocodazole arrest and mitotic shake-off were subjected to IP
using anti-BubR1 antibodies and to mass spectrometry ana-
lysis. Our ﬁndings showed that the K250 site was acetylated
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Interestingly, substrate recognition motifs of APC/C-depen-
dent ubiquitination (Peters, 2006; Thornton and Toczyski,
2006; Yu, 2007), D-box (Glotzer et al, 1991; King et al, 1996a;
Burton and Solomon, 2007) and KEN box motifs (Pﬂeger and
Kirschner, 2000; Murray and Marks, 2001; Burton and
Solomon, 2007; King et al, 2007) were found adjacent to
K250. K250 and these degrons are conserved in vertebrates
(Figure 3E), suggesting that BubR1 acetylation might regulate
SAC activity by controlling either the binding afﬁnity of
BubR1 to the Cdc20 coactivator (Burton and Solomon,
2007) or the APC/C-dependent destruction of BubR1 (King
et al, 2007).
To further conﬁrm the in vivo acetylation of BubR1, we
generated a polyclonal antibody that speciﬁcally recognizes
K250-acetylated BubR1 (Figure 4A). To verify that the anti-
Ac-K250 antibody speciﬁcally recognizes acetylated BubR1 in
M phase, interphase and M phase HeLa cell extracts were
subjected to IP with anti-BubR1 antibodies and to WB with
the antibodies indicated. Similar to the anti-Ac-K antibody,
the anti-Ac-K250 antibody recognized BubR1 only during M
phase (Figure 4B). These results conﬁrmed that the anti-Ac-
K250 antibody recognizes acetylated BubR1 in vivo.
To further assess the time point when BubR1 is acetylated
during the mitotic cell cycle, HeLa cells were synchronized in
prometaphase and then released into the cell cycle in the
presence of CHX. WB analysis with anti-acetyl-K250 serum at
different time points after release indicated that acetylation
occurred exclusively during prometaphase (time 0), but not
during the other phases of the mitotic cell cycle (Figure 4C).
This acetylation showed excellent correlation with BubR1–
PCAF complex formation (Figure 1). Furthermore, TSA-trea-
ted cells showed an attenuated level of BubR1 and acetylation
for more than 5h (Figure 4D, þTSA, anti-Ac-K250), suggest-
ing that one of the targets of TSA in mitosis might be
acetylated BubR1, supporting our interpretation from
Figure 2.
BubR1 acetylation participates in SAC activity
Substituting K250 with arginine (K250R) produces an acet-
ylation-deﬁcient mutant, whereas substituting lysine with
glutamine (K250Q) generates a mutant that mimics the
characteristics of acetylated BubR1 (Supplementary Figure
7B and C). Using these in vitro mutagenized constructs, we
determined the effect of acetylation on various aspects of SAC
activity.
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Figure 1 BubR1 interacts with PCAF and is acetylated at prometaphase kinetochores. (A) BubR1 acetylation was compared between
asynchronously growing cells and prometaphase cells. HeLa cells were treated with nocodazole for 13h (or left untreated) and subjected to
mitotic shake-off. IP was carried out with anti-Ac-K antibodies and subsequent WB with anti-BubR1 antibodies. The slower migrating form of
BubR1, phospho-BubR1 (as shown in WB of input control), was detected with the anti-Ac-K antibodies. (B) BubR1 and PCAF interact in
nocodazole-treated cells. Cells were treated with nocodazole for 13h (or left untreated), and lysates were analysed by IP with anti-PCAF,
followed by WB using anti-BubR1. The blot was then re-probed with anti-PCAF to normalize the IP. (C) BubR1 interacts with PCAF at
prometaphase kinetochores. Metaphase chromosome spreads were immunostained with anti-PCAF (red) and anti-BubR1 (green) antibodies.
PCAF localization at prometaphase kinetochores was veriﬁed by siRNA experiments (Supplementary Figure 2). White scale bar, 5mm.
(D) Images in (C) were enlarged to visualize the localization of BubR1 and PCAF with the chromosome. (E) BubR1 puriﬁed from insect cells
(left) was subjected to an in vitro acetylation assay in the presence of puriﬁed PCAF and acetyl-CoA. The reaction was analysed by WB with
anti-Ac-K antibodies (right). One mg each of BubR1 (8.4pmol) and PCAF (10.8pmol) was employed for the assay, which corresponds to a molar
ratio of 1:1.3. The same blot was re-probed with anti-BubR1 or anti-PCAF antibodies. (F) BubR1 IPs from 1mg of HeLa cell lysates were
subjected to acetylation assays with or without recombinant PCAF (1mg), followed by WB with anti-Ac-K antibodies.
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compared MPM2 staining after nocodazole treatment in cells
expressing three different BubR1 constructs (Figure 5A).
Depletion of BubR1 or Mad2 by siRNA resulted in the
abrogation of SAC function, as shown by a marked reduction
in MPM2 staining (Figure 5C, square and cross, respectively).
Wild-type and K250Q-expressing cells, depleted of endogen-
ous BubR1, restored the MPM2 staining to a level comparable
with control cells (Figure 5C, triangle and open circle,
respectively). In contrast, K250R-expressing (Figure 5C,
diamond) or K250Q-expressing cells depleted of Mad2
expression could not recover the MPM2 staining (Figure 5C,
closed circle). The importance of BubR1 acetylation for
checkpoint function was conﬁrmed by live-cell analysis.
Control cells, cells expressing wild-type BubR1, and K250Q-
expressing cells were blocked in mitosis by nocodazole
treatment. By contrast, BubR1-depleted cells (siBubR1),
Mad2-depleted cells (siMad2), cells expressing K250R
(siBubR1þK250R), and Mad2-depleted cells expressing
K250Q (siMad2þK250Q) exited from mitosis despite the
presence of nocodazole (Table I). Taken together, these
results conﬁrm that BubR1 acetylation is required for SAC
function.
We then determined whether BubR1 acetylation affected
its phosphorylation in prometaphase. HeLa cells were trans-
fected with K250R, K250Q, or wild-type (WT) BubR1 plas-
mids, synchronized at prometaphase and analysed by IP and
WB. To avoid proteolytic effects, MG132 treatments were
included. The results showed that BubR1 acetylation did
not affect the appearance of the characteristic slow-migrating
band of BubR1 in prometaphase/metaphase cells after noco-
dazole treatment (Figure 5D).
Accurate chromosome segregation is guaranteed by the
sensing of kinetochore–microtubule attachments and tension
across sister kinetochores. This signal is transmitted and
ampliﬁed by phosphorylation events in SAC components,
resulting in inhibition of the APC/C complex even when
only one chromosome is attached to spindle microtubules.
Concerted BubR1 phosphorylations play a crucial role in
spindle checkpoint signalling (Gillett and Sorger, 2001;
Taylor et al, 2001; Chen, 2002; Mao et al, 2003, 2005;
Morrow et al, 2005). It has been shown that Plk1 phosphor-
ylates BubR1 in a tension-sensitive manner and that this
event is crucial for stable kinetochore–microtubule attach-
ments (Elowe et al, 2007; Wong and Fang, 2007). To inves-
tigate whether BubR1 phosphorylation by Plk1 was affected
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Figure 2 Treatment with TSA during mitosis inhibits the degradation of BubR1 and a delay in anaphase entry. (A) HeLa cells were
synchronized at prometaphase by tyminidine–nocodazole arrest followed by mitotic shake-off, and then either released into the cell cycle (left
panel) or maintained in nocodazole for 5h (right panel). To assess the effect of HDAC inhibition on BubR1, cells were treated with 100nM of
TSA or left untreated for the indicated time points and subjected to WB; a total of 100mg/ml of cycloheximide (CHX) was included as a control
to suppress de novo protein synthesis. Blots were re-probed with an anti-Lamin A/C antibody to normalize protein levels. Attached cells
(Attach) remaining after mitotic shake-off served as controls. (B) The cell-cycle stage was assessed by propidium iodide staining and ﬂow
cytometry at the same time points as in (A); 2N and 4N DNA contents are indicated.
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recognizes Plk1-mediated BubR1 phosphorylation (Elowe
et al, 2007). In a WB of the same blot that was used to assess
BubR1 phosphorylation at prometaphase, we observed that
BubR1 acetylation did not affect Plk1-mediated phosphoryla-
tion of BubR1 in prometaphase (Figure 5D, upper panel).
Binding of BubR1 to Cdc20 is crucial in the inhibition of
APC/C activity (Tang et al, 2001; Yu, 2007; Nilsson et al,
2008). Therefore, we tested whether BubR1 acetylation af-
fected its binding to Cdc20. Our results showed that acetyla-
tion of BubR1 did not alter its direct binding to Cdc20
(Figure 5E). We then questioned whether BubR1 acetylation
affected its binding to the Cdc20 complex in nocodazole-
arrested cells. The 293Tcells transfected with various BubR1
constructs were treated with nocodazole; some were subse-
quently treated with MG132 to inhibit protein degradation.
Immunoprecipitation with 9E10 and subsequent WB showed
that the formation of a complex between BubR1 and Cdc20
in prometaphase was not affected by BubR1 acetylation
(Figure 5F).
BubR1 acetylation at K250 inhibits its ubiquitination-
dependent proteolysis
Acetylation sometimes interferes with ubiquitination-
mediated proteolysis by either competing for the same resi-
due or altering protein structure (Minucci and Pelicci, 2006).
This possibility is also supported by our observations that
BubR1 levels decreased after nocodazole arrest in the pre-
sence of CHX (Figures 2A and 4C), TSA treatment produced
higher protein levels (Figures 2A and 4D), and siRNA of PCAF
resulted in a marked reduction of BubR1 staining at prome-
taphase kinetochores (Supplementary Figure 2). Therefore,
we investigated whether BubR1 acetylation interfered with
ubiquitination-mediated proteolysis.
HeLa cells were transfected with Myc-K250R,- K250Q,o r
wild-type BubR1 expression constructs and their protein
levels assessed in the presence or absence of the MG132
proteasome inhibitor. The results indicated that K250R was
present at signiﬁcantly lower levels than wild-type BubR1 or
K250Q when de novo synthesis of proteins was inhibited
(Figure 6A, CHX). When the same set of transfected cells was
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Figure 3 Identiﬁcation of the BubR1 acetylation site. (A) The BubR1 N-terminal region (DBR2; amino acids 1–514) was subdivided into ﬁve
regions to precisely map the acetylation site. (B) GST fusions of the recombinant proteins (DBR2-1–5) were puriﬁed from Escherichia coli and
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wild-type levels (Figure 6A, MG132). Furthermore, ubiquiti-
nation of the acetylation-defective K250R mutant was con-
sistently higher than that of the wild type, whereas
ubiquitination of K250Q was markedly lower (Figure 6B).
Immunoﬂuorescence assays substantiated the observation
that BubR1 acetylation correlates with BubR1 levels. The
intensity of K250Q staining was markedly higher than that
of K250R at kinetochores when normalized to CRESTstaining
(Figure 6C and D; Supplementary Figure 8). When the
proteasome inhibitor, MG132, was included 3h before ﬁxa-
tion, K250R signals at kinetochores were restored (Figure 6C
and D), suggesting that the checkpoint defects in K250R-
expressing cells are because of insufﬁcient amounts of BubR1
at kinetochores, resulting from acetylation-deﬁcient BubR1
being susceptible to ubiquitin-mediated proteolysis. The
localization of BubR1 at kinetochores was not altered
by acetylation, which was corroborated by the ﬁnding
that Bub3 binding was not affected by BubR1 acetylation
(Supplementary Figure 9).
BubR1 acetylation/deacetylation regulates its
degradation and timing in anaphase entry
Next, we questioned whether BubR1 acetylation and degra-
dation affected the timing of mitosis. For this, we adopted
live-cell analysis coupled with ﬂuorescence measurements,
which have earlier been used efﬁciently to measure the
proteolysis of proteins in mitosis (Lindon and Pines, 2004;
Pines and Lindon, 2005; Nilsson et al, 2008). Wild-type-,
K250R-, or K250Q-expression plasmids tagged with DsRed at
their N-termini were transfected into HeLa–H2B cells de-
pleted of endogenous BubR1 by siRNA. The transfected
cells were synchronized and subjected to time-lapse imaging
(Figure 7A).
The level of wild-type BubR1 declined during mitosis; it
began to decline before the onset of anaphase and declined
further throughout mitosis (Figure 7B, blue line and 7C,
upper panel). Mitosis took an average of 57min from
nuclear envelope breakdown (NEBD) to anaphase onset in
wild-type BubR1-rescued cells (Figure 7B–D, top panel;
Supplementary movie 1 and Supplementary Figure 11).
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Similar to the anti-Ac-K antibody, anti-Ac-K250 antibodies detect only acetylated BubR1 and not K250R. Antibodies raised against acetyl-K250
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as loading controls. (B) HeLa cells in interphase (I) and M phase (M) were subjected to IP with anti-BubR1, anti-Ac-K, or anti-Ac-K250
antibodies and then immunoblotted with anti-BubR1 antibodies. BubR1 acetylation at K250 was detected in the M phase. (C) Levels of BubR1
and BubR1 acetylation after nocodazole release in the presence of CHX. HeLa cells were synchronized (time point 0), then washed and released
into the cell cycle in the presence of 100mg/ml of CHX. Lysates were prepared at the indicated time points after release and analysed by WB
with anti-BubR1 and anti-Ac-K250 antibodies. The same blot was re-probed with anti-Actin antibodies. (D) BubR1 acetylation in mitosis is
sustained by treating the cells with the pan-HDAC inhibitor TSA. WB with anti-Ac-K250 detects acetylated BubR1 exclusively at prometaphase-
arrested cells (left panel). The right panel shows cells released from nocodazole arrest in the presence of 100nM TSA, which resulted in the
attenuation of BubR1 acetylation (Ac-K250). The same blot was re-probed with anti-BubR1 and anti-Lamin A/C.
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Supplementary Figure 11) and BubR1-depleted cells took
B25min (Figure 7D; Supplementary Figures 10 and 11)
from NEBD to anaphase onset. Meanwhile, K250R intensities
declined faster than wild-type BubR1-rescued cells
(Figure 7B, red line). Furthermore, chromosomes segregated
prematurely without proper alignment at the metaphase
plane (Figure 7C, middle panel), and mitotic timing was
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Figure 5 BubR1 acetylation is required for checkpoint activity. (A–C) BubR1 acetylation is required for checkpoint activity. (A) Schematic
illustration of the experiment. HeLa cells were infected with 100 MOI of GFP-fused BubR1-WT (Ad-WT), K250R (Ad-K250R), or K250Q
(Ad-K250Q)-expressing adenovirus. Adenovirus expressing GFP only was employed for control. Five hours later, cells were depleted of
endogenous BubR1 by synthetic siBubR1 targeting the 30UTR (siBubR1) or siMad2 targeting Mad2, as marked. Nineteen hours post siRNA
transfection, cells were treated with nocodazole (200ng/ml) and aliquots of cells were collected at the indicated time points for WB (B) and
measuring mitotic index in (C). Western analysis was used to determine the levels of BubR1 and Mad2 after siRNA transfection and adenovirus
infection as indicated. (C) Comparison of the mitotic index of cells indicated after nocodazole treatment, measured by MPM2–FACS analysis
(Davis et al, 1983). (D) Acetylation of BubR1 does not directly affect its phosphorylation. HeLa cells were transfected with the indicated
plasmids and treated with nocodazole for 13h. After mitotic shake-off, cells were washed with PBS ﬁve times and incubated in the presence or
absence of 15mM of MG132 for 1.5h. Attached cells (Attach) were included for control. Lysates were prepared and subjected to IP (9E10),
followed by WB with anti-p-S676 BubR1, which detects Plk-1-mediated phosphorylated BubR1. The same blot was re-probed with 9E10
(middle panel) and anti-Ac-K250 antibodies. (E) BubR1 acetylation at K250 does not alter Cdc20 binding. Wild-type-, K250R-, and K250Q-
encoding constructs were translated in vitro in the presence of [
35S]-methionine and incubated with in vitro-translated Cdc20. Cdc20 complexes
were immunoprecipitated using an anti-Cdc20 antibody and analysed by SDS–PAGE. DBR1 (amino acids 1–322), which lacks the Cdc20-
interacting domain, a pcDNA3–myc empty vector, and reticulocyte lysate alone were included as negative controls. 5% of the in vitro-translated
products were included as input controls. (F) 293Tcells transfected with various BubR1 constructs were arrested with nocodazole, treated with
MG132 for 3h, and analysed for complex formation with Cdc20 by IP with 9E10 and by WB with anti-Cdc20 antibodies. In the lysis buffer,
10 mM of TSA was added. The same blot was re-probed with an anti-Ac-K250 antibody. Cells transfected with an empty vector (pcDNA3–myc)
were included as a negative control.
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movie 2 and Supplementary Figure 11). In contrast, intensi-
ties for K250Q did not decline for more than 3h (n¼40), the
chromosomes never segregated in those cells during the
recording, and the cells subsequently died (Figure 7B, purple
line and 7C, third row; Supplementary movie 3 and
Supplementary Figure 11). Taken together, these results in-
dicate that BubR1 destruction begins before the onset
of anaphase and that BubR1 acetylation regulates its
proteolysis. From these observations, we speculated that
BubR1 acetylation and the timed degradation of BubR1
control the correct timing for anaphase entry.
Acetylated BubR1 is an inhibitor of the APC/C complex,
whereas unacetylated BubR1 becomes a substrate of
APC/C-dependent proteolysis
We have shown that BubR1 acetylation occurs at prometa-
phase kinetochores and that BubR1 degradation began before
the onset of anaphase. These results indicate that BubR1
might become a substrate of the APC/C complex when the
SAC is satisﬁed. To test this hypothesis, we investigated
whether BubR1 was ubiquitinated by APC/C–Cdc20 complex.
HeLa cells were cotransfected with Myc-BubR1- and HA-
Cdc20-encoding plasmids and subjected to IP with 9E10 and
WB with anti-ubiquitin antibodies. The results showed that
BubR1 was polyubiquitinated by ectopic expression of Cdc20
in a dose-dependent manner (Figure 8A).
When the APC complex was inhibited by siRNA of APC3,
the level of BubR1 remained constant for 60min after noco-
dazole release in the presence of CHX, whereas it declined in
control cells (Figure 8B). This result was corroborated by the
ﬁnding from live-cell assay for proteolysis that depleting
APC3 expression abrogated the degradation of BubR1, and
concomitantly cells did not enter anaphase for more than 5h
(Supplementary Figure 12 and Supplementary movie 7).
When we compared the timing of BubR1 degradation with
Table I Frequency of exit from mitosis in 200ng/ml nocodazole
Percentage of cells exiting from mitosis (total cell number analysed)
Control 0% (n¼198)
siBubR1 100% (n¼128)
siMad2 100% (n¼97)
siBubR1+WT 6% (n¼18)
siBubR1+K250R 93% (n¼27)
siBubR1+K250Q 0% (n¼16)
siMad2+K250Q 94% (n¼17)
Experimental schemes are similar to those described in Figure 5A.
Nocodazole was continuously present and live-cell images were
taken for 18h after the start of nocodazole treatment. The number
of cells exiting from mitosis during the time course was counted.
Total cell numbers analysed (n) are indicated.
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Figure 6 BubR1 acetylation inhibits its polyubiquitination-dependent proteolysis. (A)T w omg of wild-type Myc-BubR1-, -K250R-, or -K250Q-
encoding expression plasmids was transfected into HeLa cells. The cells were then synchronized and arrested in mitosis by continuous
nocodazole treatment. The cells were then treated with MG132 or CHX for 3h in the presence of nocodazole before lysis. Total cell lysates were
analysed by WB with 9E10 to detect the ectopically expressed BubR1. The same blot was re-probed with an anti-Lamin A/C antibody. (B)
BubR1 acetylation results in the inhibition of polyubiquitination-dependent proteolysis. 293T cells were cotransfected with the plasmids
encoding wild type, K250R,o rK250Q with HA–Ubiquitin, and proteins were immunoprecipitated with 9E10 and analysed by WB using a 12CA5
anti-HA antibody to detect polyubiquitination of BubR1 [(Ub)n–BubR1]. The blot was re-probed with 9E10 to control for the amount of
immunoprecipitation. (C) HeLa cells were transfected as in (A). At 16h post transfection, the cells were treated with 100mM of monastrol to
arrest the cells in prometaphase without disturbing microtubule structures. After 5h, cells were treated with MG132 (þMG132) or left
untreated. Cells were then ﬁxed and co-stained with 9E10 (red) and CREST (green). Other phases of mitosis are illustrated in Supplementary
Fig 8. Bars, 5mm. (D) Quantiﬁcation of results in (C). Histograms summarize three different BubR1 intensities at kinetochores in the absence or
presence of MG132, measured by staining with 9E10 and normalized for CREST staining. Results are from two independent experiments
(mean±s.e.m.; nX8 prometaphase cells per experiment, Po0.01).
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Cyclin B, Plk1, and Aurora A, we found that BubR1
degradation began before that of Cyclin B (Supplementary
Figure 13).
Next, we tested whether Cdc20 was responsible for BubR1
degradation during mitosis. To prevent the cells from exiting
mitosis before the analysis began, HeLa cells were transfected
with an expression construct to force moderate expression of
B
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Figure 7 BubR1 acetylation inhibits its degradation and regulates the timing of anaphase onset. The HeLa cells stably expressing histone H2B–
GFP (HeLa–H2B) were co-transfected with synthetic siBubR1 targeting the 30UTR and WT, K250R,o rK250Q expression plasmids, respectively,
tagged with DsRed at the N-termini using lipofectamineTM 2000 and subjected to time-lapse microscopy. (A) Schematic illustration of the
experiment. At 13h after transfection, cells were synchronized at the S phase through the addition of 2mM thymidine to the culture. After a
further 13h, cells were washed from the thymidine block and released into the cell cycle. Images were taken starting at 8h after release and
were processed for 18h. (B) Fluorescence intensities (red) and mitotic timing (segregation of green) were measured and scored from NEBD.
Mean red ﬂuorescence was measured and plotted on the Y-axis as pixel values using Image J. The X-axis represents the time from NEBD in
minutes. The curves shown are representative examples of several transfected cells from at least three separate experiments. Arrows indicate
the timing of anaphase onset. (C) Captured images of (B) at indicated time points (marked at lower right). NEBD is marked as 00:00. BubR1
ﬂuorescence (DsRed) images are shown in the bottom panels in grayscale to facilitate the measurement of ﬂuorescence intensities for
WT BubR1 (Supplementary movie 1), K250R (Supplementary movie 2), and K250Q (Supplementary movie 3), respectively. In the case of
K250Q-rescued cells, cells were arrested in prometaphase for hours, then the cells frequently died. In the K250R-rescued cell, anaphase began
without alignment of chromosomes in metaphase plane, and the mitotic timing was shortened to B25min. Stages in mitosis were determined
from chromosome morphology. It should be noted that the ﬂuorescence intensity around kinetochores declined before the onset of anaphase in
WT- and K250R-expressing cells. Fluorescence intensity around kinetochores in K250Q-expressing cell did not decline for hours. (D) Box plot
distributions of statistical mitotic timings from NEBD to anaphase onset for control HeLa cells (n¼60); after depletion of BubR1 (siBubR1)
(n¼65); WT BubR1-transfected cells rescued from BubR1 depletion (n¼21); K250R transfection after siRNA of BubR1 (n¼43); and K250Q
transfection after siBubR1 (n¼40). The bars in the box are the median values. Outliers (open circle) and suspected outliers (asterisk) as
determined by statistical analysis are shown. Box plots were drawn again on a smaller Y-axis scale, without K250Q-rescued data, in the right
panel to facilitate the comparisons of mitotic timing. Data are from three independent experiments analysing 20–65 transfected cells using SPSS
software.
BubR1 acetylation regulates timing of mitosis
EC h o iet al
&2009 European Molecular Biology Organization The EMBO Journal VOL 28 | NO 14 | 2009 2085D
F
Prometaphase
APC/C inhibited
Anaphase onset
APC/C activation
Bipolar KT–MT achieved
Ac
APC/C
BubR1
Ub
Ub
Ub
APC/C
BubR1
PCAF
Ub
Ub
Ub
WB: α-BubR1
WB: α-CyclinB
WB: α-LaminA/C
siGFP siCdc20#1 siCdh1 siCdc20#2
CHX 0 15 30 60 0 15 30 60 0 15 30 60 0 15 30 60 (min)
B A
Myc–BubR1
HA–CDC20
+
–
++
WB: 12CA5
WB: 9E10
IP: 9E10
WB: α-Ubi
IP: 9E10
WB: 9E10
I
n
p
u
t
 
(
5
%
)
siGFP
siAPC3#1
siAPC3#2
CHX 0 60 0 60 0 60
WB: α-BubR1
WB: α-APC3
WB: α-Actin
(min)
115
90.5
Mr(K)
C
WB: α-Cdc20
WB: α-Cdh1
WB: α-LaminA/C
siGFP
siCdc20#1
siCdh1
siCdc20#2
0.00E+00
2.00E+03
4.00E+03
6.00E+03
8.00E+03
1.00E+04
–5
20
40
60
80
100
120
140
160
180
200
siBubR1+WT_AXXA
siBubR1+K250R_AXXA
siBubR1+K250Q_AXXA
siBubR1+K250R
NEBD
Time relative to NEBD (min)
F
l
u
o
r
e
s
c
e
n
c
e
 
(
D
s
R
e
d
)
Time relative to NEBD (min)
F
l
u
o
r
e
s
c
e
n
c
e
 
(
D
s
R
e
d
)
0.00E+00
2.00E+03
4.00E+03
6.00E+03
8.00E+03
1.00E+04
–5
20
45
70
95
120
145
170
195
NEBD
siBubR1+WT_KEN1,2 (AAA)
siBubR1+K250R_KEN1,2 (AAA)
siBubR1+K250Q_KEN1,2 (AAA)
siBubR1+K250R
E
Figure 8 K250 acetylation functions as a switch between APC/C inhibition and APC/C-dependent BubR1 destruction. (A) 293T cells were co-
transfected with Myc-tagged BubR1 (1mg each) and HA-tagged CDC20 expression constructs in a dose-dependent manner (0, 1, and 2mg). Lysates
were then subjected to IP with 9E10 and to WB with anti-ubiquitin antibody. The blot was re-probed with 9E10 to control for the amount of IP.
(B) BubR1 protein levels were compared after knockdown expressions of APC3 to assess whether the APC/C complex was responsible for BubR1
degradation. HeLa cells were transfected with synthetic siRNAs. At 60h later, cells were treated with 200ng/ml nocodazole for 12h, and the mitotic
cells were collected by mitotic shake-off. Lysates were prepared before and after CHX addition for 1h. Note that after nocodazole release for 60min in
the presence of CHX, APC3 appears as a faster migrating form, indicating that APC3 is highly modiﬁed in prometaphase. (C)W Ba n a l y s i so fC d c 2 0
and Cdh1 after transfection of siRNAs, as indicated. These cells were used to measure BubR1 levels in (D). (D) Experiments were carried out in a
manner similar to (B), except that, to block the exit from mitosis, a Cyclin B expression construct was transfected simultaneously with siRNAs. The
lysates for WB were collected at 0, 15, 30, and 60min after nocodazole release and CHX treatment. (E) Intensities of ﬂuorescence, which reﬂects the
level of DsRed–BubR1 in mitotic cells, were recorded against time relative to NEBD. The D-box or the KEN boxes were destroyed by in vitro
mutagenesis in DsRed–K250R by substituting AAA for KEN boxes (left panel) and RXXL to AXXA for the D-box (right panel). The curves shown are
representative of at least 20 individual cells from at least two separate experiments. A ﬂuorescence intensity curve for K250R was included in all
e x p e r i m e n t sa sac o n t r o l .( F) Our working model for BubR1 acetylation and the regulation of APC/C activity. BubR1 is in a complex with Cdc20 and
APC/C through its KEN1, KEN2, and D-box domains. BubR1 acetylation/deacetylation changes the surface structure of degrons in relation to APC/
C–Cdc20 complex. When kinetochores are not yet attached to spindles (prometaphase), BubR1 is acetylated by PCAF. BubR1 acetylation prevents it
from being a substrate of the APC/C complex, and acetylated BubR1 is a potent inhibitor of the APC/C–Cdc20 complex. When all kinetochores are
stably attached to spindles, BubR1 is no longer acetylated because of a change in the stoichiometry of the BubR1 complex or its deacetylation. The
conformational change allows the D-box and KEN box degrons of BubR1 to be recognized as a substrate of the APC/C-Cdc20 complex. In our model,
the mode of Cdc20 binding to APC/C complex and BubR1 changes, depending on the status of BubR1 acetylation.
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transfected. After 16h of transfection, cells were synchro-
nized at prometaphase, followed by release in the presence of
CHX. Cell lysates were prepared at indicated time points after
release and the levels of BubR1 and Cylin B were analysed.
The results showed that BubR1 degradation was inhibited in
cells depleted of Cdc20, whereas control cells (siGFP) showed
signiﬁcant decreases in BubR1 compared with initial analysis
after nocodazole release. Cyclin B levels in the same blot
showed that cells were in mitosis for at least 30min after
nocodazole release (Figure 8D). These results suggest that
BubR1 is degraded through APC/C–Cdc20-dependent ubiqui-
tination during mitosis.
Cdh1, a homologue of Cdc20, serves as a coactivator of
APC/C complex during mitotic exit. Therefore, we asked
whether Cdh1 was also responsible for BubR1 degradation.
When cells were depleted of Cdh1 (siCdh1), BubR1 levels
decreased during mitosis. However, in Cdh1-depleted cells,
BubR1 levels remained similar between 30 and 60min after
nocodazole release, whereas control cells (siGFP) had a
continuous decrease after release (Figure 8D). It should be
noted that the level of Cyclin B declined between 30 and
60min after release, indicating that cells are exiting from
mitosis within 60min after release. The result suggests that
BubR1 is subjected to a second round of degradation during
mitotic exit through APC/C–Cdh1-mediated ubiquitination.
If the destruction of BubR1 by the APC/C–Cdc20 complex
is important for mitotic timing, the proteolysis of BubR1
might depend on its degrons, the D-box and KEN boxes. To
test this hypothesis, we made BubR1 constructs in which the
D-box or KEN boxes were destroyed in DsRed-WT,- K250R,
and -K250Q expression vectors. HeLa cells depleted of en-
dogenous BubR1 and transfected with various plasmids were
subjected to live-cell analysis for proteolysis, as shown in
Figure 7. The result showed that both KEN1 and KEN2-
mutated (KEN1, 2 (AAA)) or D-box-mutated WT, K250Q,
and K250R were stable during the recorded times, whereas
K250R with intact degrons began to degrade B20min after
NEBD (Figure 8E). We also observed that when KEN boxes or
the D-box was destroyed in BubR1, cells were not able to
maintain the SAC, and the mitosis was accelerated, although
BubR1 level remained constant (Supplementary movie 6).
To conﬁrm that BubR1 degradation depended on the D-box
and KEN boxes, we carried out WB analysis in HeLa cells
transfected with various constructs. As it was impossible to
obtain a similar mitotic index and synchronize the cells after
BubR1 siRNA and K250R, WT,o rK250Q transfection, we
compared the level of ectopically expressed proteins in the
presence of endogenous BubR1 (Supplementary Figure 14).
The result corroborated the ﬁnding that the KEN box- or D-
box-deleted K250R mutants were stable (Supplementary
Figure 14B, middle and right panels). Collectively, these
results suggest that the APC/C complex is responsible for
BubR1 degradation, and BubR1 degradation requires the
D-box and KEN boxes.
Discussion
In this study, we provide compelling evidence that BubR1 is
acetylated at K250 by PCAF speciﬁcally at prometaphase.
Acetylated BubR1 is a potent inhibitor of the APC/C–Cdc20
complex, whereas unacetylated (or deacetylated) BubR1
readily becomes a substrate of APC/C-dependent proteolysis.
Thus, BubR1 acetylation/deacetylation serves as a molecular
switch for the conversion of BubR1 from inhibiting the APC/
C complex to becoming its substrate. This Janus-like mode of
action provides an efﬁcient way of controlling chromosome
segregation after checking that everything is ready, which is a
crucial requirement for accurate sister chromatid separation.
A similar mode of switching from an inhibitor to a substrate
of the APC/C complex has been reported in Emi1, an in-
hibitor of the APC/C–Cdh1 complex in interphase (Miller
et al, 2006). Interestingly, a recent report suggested that
Cdc20 serves as a substrate of APC/C complex when the
SAC is activated and as a coactivator of APC/C complex
during the metaphase–anaphase transition (Nilsson et al,
2008).
Our working hypothesis is as follows: BubR1 acetylation at
K250 takes place at prometaphase, which inhibits the APC/
C–Cdc20 complex until all the kinetochores are stably at-
tached with bipolar spindles. This monitoring of microtubule
attachment probably involves the motor protein CENP-E
(Chan et al, 1999; Abrieu et al, 2000; Yao et al, 2000; Mao
et al, 2003, 2005; Morrow et al, 2005; Zhang et al, 2008).
When the spindle checkpoint is satisﬁed, BubR1 is no longer
acetylated and the unacetylated form of BubR1 replaces
acetylated BubR1. This process might involve the deacetyla-
tion of BubR1, because we observed that HDAC 1–3 could
bind to BubR1. However, whether dynamic acetylation and
deacetylation of BubR1 take place during mitosis has not yet
been investigated. Another possibility is that PCAF detaches
from BubR1 after all of the kinetochores are stably attached to
spindles, because the BubR1 complex involving CENP-E and
microtubules is very likely to change its stoichiometry. In
support of the ﬁrst view, a recent report showed that HDAC3
localizes to spindle microtubules and is required for kineto-
chore–microtubule attachments (Ishii et al, 2008). As for the
latter view, we have shown that the BubR1–PCAF interaction
takes place exclusively at prometaphase kinetochores
(Figure 1).
Turning the APC/C–Cdc20 complex on and off
The timed proteolysis of key regulators of the cell cycle is
vital for progression through mitosis. Regulated proteolysis in
cell division is largely dependent on the APC/C E3 ligase
activity. For APC/C activation, the WD40 domain-containing
coactivator Cdc20 or its homologue Cdh1 is required (Peters,
2006; Thornton and Toczyski, 2006; Yu, 2007). It was sug-
gested that coactivators recognize the destruction signals
(D-box or KEN box) and transfer them to the APC/C complex
for polyubiquitination. However, accumulating evidence in-
dicates that both the D-box and the KEN box degrons are
recognized by the APC/C complex as well. Furthermore, it
was convincingly shown in Xenopus extracts that destruction
signals are recognized and bound by the APC but not the
Cdc20 coactivator (Yamano et al, 2004). Therefore, it is
possible that BubR1 binds to Cdc20 and the APC simulta-
neously through its degrons. It is noteworthy that a recent
structural analysis using single-particle electron microscopy
showed that the APC/C interaction domain partially overlaps
with the Cdc20 binding site on BubR1 (Herzog et al, 2009).
How, then, can BubR1 avoid degradation while binding to
and inhibiting the APC/C–Cdc20 complex? When two KEN
boxes or a D-box was destroyed in WT BubR1, K250Q, or
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levels of BubR1 did not decrease. We believe this was because
of the inability of BubR1 to bind to the APC/C complex and
Cdc20 in the absence of its degron domains. The acetylation
status of BubR1 does not affect Cdc20 binding (Figure 5).
Therefore, the availability and the binding mode of individual
KEN1, KEN2, and D-box degrons for binding to APC/C–
Cdc20 complex might depend on BubR1 acetylation and
bipolar spindle attachment. Notably, a recent report showed
that BubR1 binds and presents Cdc20 to promote APC/C-
mediated Cdc20 degradation when SAC is active (Nilsson
et al, 2008). Taken together with our ﬁndings, we postulate
that in SAC-on conditions, BubR1 is acetylated and Cdc20
degradation is promoted. When all the chromosomes are
attached to spindle microtubules, BubR1 is deacetylated (or
no longer acetylated) because of conformational changes
after spindle attachment. The structure of BubR1-containing
complex changes, and the degrons of BubR1 are exposed to
APC/C complex and Cdc20 and serve as substrate recognition
motifs for the APC/C–Cdc20 complex. Thereafter, destruction
of BubR1 might result in additional activation of the APC/C–
Cdc20 complex (Figure 8F). Validation of this hypothesis will
require further study.
Studies from yeast have shown that Mad3 is capable of
binding to Cdc20 but is not degraded by the APC/C complex
(Burton and Solomon, 2007). We wish to point out that there
is a marked difference in BubR1/Mad3 acetylation and pro-
teolysis between yeast and mammals. The acetylation site
K250 and its neighbouring degrons are not really conserved
between yeast Mad3 and hBubR1. Yeast Mad3 was not
acetylated in our in vitro acetylation assays (Supplementary
Figure 15). Thus, vertebrate BubR1 has acquired additional
multilayered regulatory functions in evolution.
BubR1 is ubiquitinated and degraded in two steps: ﬁrst
through APC/C–Cdc20 complex and then through APC/
C–Cdh1 complex
With compelling lines of evidence, we have shown that the
APC/C–Cdc20 complex is responsible for BubR1 destruction
in mitosis, although we were not able to detect polyubiqui-
tinated chains on BubR1 using in vitro ubiquitination assays.
As with Cyclin B, this could be because of the as-yet-uni-
dentiﬁed biochemical nature of in vitro-translated BubR1.
Owing to aggregation, full-length Cyclin B is not an efﬁcient
substrate of the APC/C complex, in vitro (Pﬂeger and
Kirschner, 2000; Yamano et al, 2004). Interestingly, we
found that APC/C–Cdh1 complex was responsible for
BubR1 degradation after exit from mitosis, similar to the
yeast Mad3 (King et al, 2007) and Bub1 (Qi and Yu, 2007).
Our results suggest that BubR1 is degraded in two steps: ﬁrst
during mitosis and then during mitotic exit.
We have shown earlier that BubR1 is activated when
mitotic cells encounter DNA damage (Choi and Lee, 2008).
As the DNA damage response is central to cancer develop-
ment, forced activation of BubR1 in mitosis might be helpful
in the treatment of cancer. Furthermore, inhibitors of histone
deacetylases have proven to be successful in many preclinical
cancer models and have shown encouraging results in clin-
ical trials (Minucci and Pelicci, 2006). Therefore, our results
imply that BubR1-speciﬁc inhibition of deacetylation might
be a promising target for future cancer therapeutics.
Materials and methods
Mouse and rabbit polyclonal antibodies generated against
acetylated BubR1
Antibodies speciﬁc to BubR1 acetylated at K250 were generated by
injecting mice or rabbits with the synthetic peptide chemically
acetylated at K250 (-CGGAL(AcK)APSQ-C), corresponding to hu-
man BubR1 245–254 amino acids (Peptron, Korea). Anti-Ac-K250
antiserum was raised against the peptide.
Note: Additional Materials and methods are provided in the
Supplementary data.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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